Onco Wiki / drapeau rouge

CML high-risk by ELTS (EUTOS Long-Term Survival score) — favors 2nd-generation TKI (nilot...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-CML-HIGH-RISK-ELTS
TypeSignal d’alerte
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesDIS-CML
SourcesSRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-NCCN-MPN-2025

Origine du drapeau rouge

DéfinitionCML high-risk by ELTS (EUTOS Long-Term Survival score) — favors 2nd-generation TKI (nilotinib / dasatinib / bosutinib) over imatinib for faster deep molecular response and improved long-term outcomes
Direction cliniqueintensifier
Catégoriehigh-risk-biology
Algorithme de décalageALGO-CML-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "cml_elts_risk",
      "value": "high"
    },
    {
      "finding": "cml_sokal_risk",
      "value": "high"
    },
    {
      "finding": "cml_eutos_risk",
      "value": "high"
    }
  ],
  "type": "risk_score"
}

Notes

ELN 2020 prefers ELTS over Sokal for predicting CML-related death and guiding 1L TKI selection in younger patients seeking treatment-free remission. High-risk patients gain more from 2nd-gen TKIs in early deep molecular response, but no consistent OS difference vs imatinib. Comorbidity profile (RF-CML-COMORBIDITY-COMPLEX) co-determines which 2nd-gen agent. STUB — requires clinical co-lead signoff.

Utilisé par

Algorithmes

Indication

Signal d’alerte